Olemedia/E+ via Getty Images
It's a new week, with yet more signs that the China-U.S. IPO pipeline is slowly creaking back to life. This time it's a relatively small IPO by a medical device maker named Meihua International Medical Technologies
Medical Device Maker Highlights China Risk As Chinese U.S. IPOs Resume
Summary
- Meihua International files updated prospectus highlighting China oversight risk in latest filing for its modest $57 million U.S. IPO.
- Hotel operator Atour makes similar updated filing for U.S. IPO plan to raise $350 million, valuing the company at more than $2 billion.
- LianBio's shares fizzle in its trading debut, falling 14% on its first trading day, as it became the first major New York listing by a Chinese company since a halt in July.
Bamboo Works provides news on Chinese companies listed in Hong Kong and the United States, with a strong focus on mid-cap and also pre-IPO companies. Our founding team has more than a century of experience in Chinese and global media and capital markets, working for names including the Wall Street Journal, Reuters, Alibaba and JPMorgan. Drawing on that background, we provide in-depth coverage to drive informed decision-making for investors and others interested in this dynamic group of companies, many of them overlooked by mainstream media.